1. Eddy A.A., Neilson E.G.. Chronic kidney disease progression.
J Am Soc Nephrol 17:2006;2964–2966.
2. Bottinger E.P.. TGF-beta in renal injury and disease.
Semin Nephrol 27:2007;309–320.
3. Wang W., Koka V., Lan H.Y.. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10:2005;43–56.
4. Roberts A.B.. Molecular and cell biology of TGF-beta.
Miner Electrolyte Metab 24:1998;111–119.
5. Derynck R., Zhang Y.E.. Smad-dependent and Smad-independent pathways in TGFbeta family signalling.
Nature 425:2003;577–584.
6. Schnaper H.W., Hayashida T., Poncelet A.C.. It's a Smad world: regulation of TGF-beta signaling in the kidney.
J Am Soc Nephrol 13:2002;1126–1128.
7. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., Wrana J.L.. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation.
Mol Cell 6:2000;1365–1375.
8. Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T., Miyazono K.. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation.
J Biol Chem 276:2001;12477–12480.
9. Lan H.Y.. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells.
Curr Opin Nephrol Hypertens 12:2003;25–29.
10. Li J., Bertram J.F.. Review: endothelial-myofibroblast transition, a new player in diabetic renal fibrosis.
Nephrology (Carlton) 15:2010;507–512.
11. Border W.A., Noble N.A.. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy.
Kidney Int 54:1998;1390–1391.
12. Kopp J.B., Factor V.M., Mozes M., Nagy P., Sanderson N., Bottinger E.P., Klotman P.E., Thorgeirsson S.S.. FTransgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.
Lab Invest 74:1996;991–1003.
13. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A.B., Sporn M.B., Thorgeirsson S.S.. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.
Proc Natl Acad Sci USA 92:1995;2572–2576.
14. Letterio J.J., Roberts A.B.. Regulation of immune responses by TGF-beta.
Annu Rev Immunol 16:1998;137–161.
15. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., Annunziata N., Doetschman T.. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.
Nature 359:1992;693–699.
16. Li M.O., Wan Y.Y., Flavell R.A.. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation.
Immunity 26:2007;579–591.
17. Li M.O., Sanjabi S., Flavell R.A.. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms.
Immunity 25:2006;455–471.
18. Wang W., Huang X.R., Li A.G., Liu F., Li J.H., Truong L.D., Wang X.J., Lan H.Y.. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7.
J Am Soc Nephrol 16:2005;1371–1383.
19. Huang X.R., Chung A.C., Wang X.J., Lai K.N., Lan H.Y.. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease.
Am J Physiol Renal Physiol 295:2008;F118–F127.
20. Huang X.R., Chung A.C., Zhou L., Wang X.J., Lan H.Y.. Latent TGF-beta1 protects against crescentic glomerulonephritis.
J Am Soc Nephrol 19:2008;233–242.
21. Lan H.Y., Chung A.C.. Transforming growth factor-β and Smads.
Contrib Nephrol 170:2011;75–82.
22. Li J.H., Huang X.R., Zhu H.J., Oldfield M., Cooper M., Truong L.D.. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease.
Faseb J 18:2004;176–178.
23. Chung A.C., Zhang H., Kong Y.Z., Tan J.J., Huang X.R., Kopp J.B.. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.
J Am Soc Nephrol 21:2010;249–260.
24. Wang W., Huang X.R., Canlas E., Oka K., Truong L.D., Deng C.. Essential role of Smad3 in angiotensin II-induced vascular fibrosis.
Circ Res 98:2006;1032–1039.
25. Yang F., Chung A.C., Huang X.R., Lan H.Y.. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3.
Hypertension 54:2009;877–884.
26. Yang F., Huang X.R., Chung A.C., Hou C.C., Lai K.N., Lan H.Y.. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition.
J Pathol 221:2010;390–401.
27. Fujimoto M., Maezawa Y., Yokote K., Joh K., Kobayashi K., Kawamura H.. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy.
Biochem Biophys Res Commun 305:2003;1002–1007.
28. Isono M., Chen S., Hong S.W., Iglesias-de la Cruz M.C., Ziyadeh F.N.. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells.
Biochem Biophys Res Commun 296:2002;1356–1365.
29. Chen H., Huang X.R., Wang W., Li J., Heuchel R.L., Chung A.C.. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential.
Diabetes 60:2010;590–601.
30. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A.. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
J Clin Invest 112:2003;1486–1494.
31. Lan H.Y., Mu W., Tomita N., Huang X.R., Li J.H., Zhu H.J., Morishita R., Johnson R.J.. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model.
J Am Soc Nephrol 14:2003;1535–1548.
32. Terada Y., Hanada S., Nakao A., Kuwahara M., Sasaki S., Marumo F.. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney.
Kidney Int 61:2002;94–98.
33. Chung A.C., Huang X.R., Zhou L., Heuchel R., Lai K.N., Lan H.Y.. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice.
Nephrol Dial Transplant 24:2009;1443–1454.
34. Hou C.C., Wang W., Huang X.R., Fu P., Chen T.H., Sheikh-Hamad D., Lan H.Y.. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney.
Am J Pathol 166:2005;761–771.
35. Zhou L., Fu P., Huang X.R., Liu F., Chung A.C., Lai K.N., Lan H.Y.. Mechanism of chronic aristolochic acid nephropathy: role of Smad3.
Am J Physiol Renal Physiol 298:2010;F1006–F1017.
36. Ka S.M., Huang X.R., Lan H.Y., Tsai P.Y., Yang S.M., Shui H.A., Chen A.. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice.
J Am Soc Nephrol 18:2007;1777–1788.
37. Verrecchia F., Chu M.L., Mauviel A.. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach.
J Biol Chem 276:2001;17058–17062.
38. Li J., Qu X., Yao J., Caruana G., Ricardo S.D., Yamamoto Y., Yamamoto H., Bertram J.F.. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.
Diabetes 59:2010;2612–2624.
39. Meng X.M., Huang X.R., Chung A.C., Qin W., Shao X., Igarashi P., Ju W., Bottinger E.P., Lan H.Y.. Smad2 Protects against TGF-{beta}/Smad3-Mediated Renal Fibrosis.
J Am Soc Nephrol 21:2010;1477–1487.
40. Zhou Y., Mao H., Li S., Cao S., Li Z., Zhuang S., Fan J., Dong X., Borkan S.C., Wang Y., Yu X.. HSP72 inhibits Smad3 activation and nuclear translocation in renal epithelial-to-mesenchymal transition.
J Am Soc Nephrol 21:2010;598–609.
41. Ng Y.Y., Chen Y.M., Tsai T.J., Lan X.R., Yang W.C., Lan H.Y.. Pentoxifylline inhibits transforming growth factor-β signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats.
Am J Nephrol 29:2009;43–53.
42. Kang D.H., Joly A.H., Oh S.W., Hugo C., Kerjaschki D., Gordon K.L., Mazzali M., Jefferson J.A., Hughes J., Madsen K.M., Schreiner G.F., Johnson R.J.. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.
J Am Soc Nephrol 12:2001;1434–1447.
43. Kang D.H., Hughes J., Mazzali M., Schreiner G.F., Johnson R.J.. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function.
J Am Soc Nephrol 12:2001;1448–1457.
44. Martin A., Komada M.R., Sane D.C.. Abnormal angiogenesis in diabetes mellitus.
Med Res Rev 23:2003;117–145.
45. Nakagawa T., Li J.H., Garcia G., Mu W., Piek E., Böttinger E.P., Chen Y., Zhu H.J., Kang D.H., Schreiner G.F., Lan H.Y., Johnson R.J.. TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways.
Kidney Int 66:2004;605–613.
46. Meng X.M., Huang X.R., Xiao J., Chung A.C., Qin W., Chen H.Y., Lan H.Y.. Disrupted Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation in renal inflammation and fibrosis in vivo and in vitro.
Kidney Int 81:2012;266–279.
47. von Gersdorff G., Susztak K., Rezvani F., Bitzer M., Liang D., Böttinger E.P.. Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta.
J Biol Chem 275:2000;11320–11326.
48. Afrakhte M., Moren A., Jossan S., Itoh S., Sampath K., Westermark B., Heldin C.H., Heldin N.E., ten Dijke P.. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members.
Biochem Biophys Res Commun 249:1998;505–511.
49. Zhu H.J., Iaria J., Sizeland A.M.. Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways.
J Biol Chem 274:1999;32258–32264.
50. Liu F.Y., Li X.Z., Peng Y.M., Liu H., Liu Y.H.. Arkadia regulates TGFβ signaling during renal tubular epithelial to mesenchymal cell transition.
Kidney Int 73:2008;588–594.
51. Fukasawa H., Yamamoto T., Togawa A., Ohashi N., Fujigaki Y., Oda T., Uchida C., Kitagawa K., Hattori T., Suzuki S., Kitagawa M., Hishida A.. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice.
Proc Natl Acad Sci USA 101:2004;8687–8692.
52. Inoue Y., Imamura T.. Regulation of TGF-beta family signaling by E3 ubiquitin ligases.
Cancer Sci 99:2008;2107–2112.
53. Tan R., He W., Lin X., Kiss L.P., Liu Y.. Smad ubiquitination regulatory factor-2 in the fibrotic kidney: regulation, target specificity, and functional implication.
Am J Physiol Renal Physiol 294:2008;F1076–F1083.
54. Kantharidis P., Wang B., Carew R.M., Lan H.Y.. Diabetes complications: the microRNA perspective.
Diabetes 60:2011;1832–1837.
55. Chung A.C., Huang X.R., Meng X., Lan H.Y.. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis.
J Am Soc Nephrol 21:2010;1317–1325.
56. Zhong X., Chung A.C., Chen H.Y., Meng X., Lan H.Y.. miR-21 is regulated by TGF-ß via Smad3, not Smad2, dependent mechanism and is a therapeutic target for renal fibrosis.
J Am Soc Nephrol 22:2011;1668–1681.
57. Qin W., Chung A.C., Huang X.R., Meng X.M., Hui D.S., Yu C.M., Sung J.J., Lan H.Y.. TGF-{beta}/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.
J Am Soc Nephrol 22:2011;1462–1474.
58. Wang B., Koh P., Winbanks C., Coughlan M.T., McClelland A., Watson A., Jandeleit-Dahm K., Burns W.C., Thomas M.C., Cooper M.E., Kantharidis P.. miR-200a Prevents renal fibrogenesis through repression of TGF-b2 expression.
Diabetes 60:2011;280–287.
59. Lan H.Y.. Smad7 as a therapeutic agent for chronic kidney diseases.
Front Biosci 13:2008;4984–4992.
60. Li J.H., Zhu H.J., Huang X.R., Lai K.N., Johnson R.J., Lan H.Y.. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation.
J Am Soc Nephrol 13:2002;1464–1472.
61. Ng Y.Y., Hou C.C., Wang W., Huang X.R., Lan H.Y.. Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int 94(Suppl):2005;S83–S91.
62. Kanamaru Y., Nakao A., Mamura M., Suzuki Y., Shirato I., Okumura K., Tomino Y., Ra C.. Blockade of TGF-beta signaling in T cells prevents the development of experimental glomerulonephritis.
J Immunol 166:2001;2818–2823.
63. Lallemand F., Mazars A., Prunier C., Bertrand F., Kornprost M., Gallea S., Roman-Roman S., Cherqui G., Atfi A.. Smad7 inhibits the survival nuclear factor κB and potentiates apoptosis in epithelial cells.
Oncogene 20:2002;879–884.
64. Schiffer M., Bitzer M., Roberts I.S., Kopp J.B., Dijke P., Mundel P., Bottinger E.P.. Apoptosis in podocytes induced by TGF-β and Smad7.
J Clin Invest 108:2001;807–816.
65. Schiffer M., Schiffer L.E., Gupta A., Shaw A.S., Roberts I.S., Mundel P., Bottinger E.P.. Inhibitory smads and tgf-β signaling in glomerular cells.
J Am Soc Nephrol 13:2002;2657–2666.
66. Okado T., Terada Y., Tanaka H., Inoshita S., Nakao A., Sasaki S.. Smad7 mediates transforming growth factor-β-induced apoptosis in mesangial cells.
Kidney Int 62:2002;1178–1186.
67. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., Roberts A.B., Deng C.. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.
EMBO J 18:1999;1280–1291.